The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of “Stealthy” Nanomaterials
Open accessAbstract
In the last decades, the staggering progress in nanotechnology brought around a wide and heterogeneous range of nanoparticle-based platforms for the diagnosis and treatment of many diseases. Most of these systems are designed to be administered intravenously. This administration route allows the nanoparticles (NPs) to widely distribute in the body and reach deep organs without invasive techniques. When these nanovectors encounter the biological environment of systemic circulation, a dynamic interplay occurs between the circulating proteins and the NPs, themselves. The set of proteins that bind to the NP surface is referred to as the protein corona (PC). PC has a critical role in making the particles easily recognized by the innate immune system, causing their quick clearance by phagocytic cells located in organs such as the lungs, liver, and spleen. For the same reason, PC defines the immunogenicity of NPs by priming the immune response to them and, ultimately, their immunological toxicity. Furthermore, the protein corona can cause the physical destabilization and agglomeration of particles. These problems induced to consider the PC only as a biological barrier to overcome in order to achieve efficient NP-based targeting. This review will discuss the latest advances in the characterization of PC, development of stealthy NP formulations, as well as the manipulation and employment of PC as an alternative resource for prolonging NP half-life, as well as its use in diagnostic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002 · cited 1×
“The use of different moieties has been extensively discussed in other works and goes beyond the scope of the present paper (Blanco et al., 2015; Parodi et al., 2015).”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Biodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,920
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology
Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.181 · Cited by 2,283
Salvati, A., Pitek, A. S., Monopoli, M. P., Prapainop, K., Bombelli, F. B., Hristov, D. R., Kelly, P. M., Åberg, C., Mahon, E., & Dawson, K. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.237 · Cited by 1,912
Nanoparticle–liver interactions: Cellular uptake and hepatobiliary elimination
Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D., & Chan, W. C. W. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.020 · Cited by 1,349
Schöttler, S., Becker, G., Winzen, S., Steinbach, T., Mohr, K., Landfester, K., Mailänder, V., & Wurm, F. R. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.330 · Cited by 1,272
Progress in Nanomedicine: Approved and Investigational Nanodrugs.
Ventola, C. L. (2017) · Europe PMC (PubMed Central) · Cited by 835
Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces
Vroman, L., Adams, A., Fischer, G., & Munoz, P. (1980) · Blood · doi:10.1182/blood.v55.1.156.156 · Cited by 781
Cited by
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Lipid-based nanoparticle technologies for liver targeting
Böttger, R., Pauli, G., Chao, P.-H., AL Fayez, N., Hohenwarter, L., & Li, S.-D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.017 · Cited by 264
Janjua, T. I., Cao, Y., Kleitz, F., Linden, M., Yu, C., & Popat, A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115115 · Cited by 259
The effects of protein corona on in vivo fate of nanocarriers
Xiao, Q., Zoulikha, M., Qiu, M., Teng, C., Lin, C., Li, X., Sallam, M. A., Xu, Q., & He, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114356 · Cited by 255
Non-immunotherapy application of LNP-mRNA: Maximizing efficacy and safety
Vlatkovic, I. (2021) · Biomedicines · doi:10.3390/biomedicines9050530 · Cited by 112
Metadata
- Authors
- Rampado, R., Crotti, S., Caliceti, P., Pucciarelli, S., & Agostini, M.
- Venue
- Frontiers in Bioengineering and Biotechnology
- Publisher
- Frontiers Media SA
- Published
- 2020-04-03
- Volume
- 8
- Pages
- 166-166
- ISSN
- 2296-4185 (ISSN-L)
- OpenAlex
- W3014236874
- Cited by
- 390
- References
- 87
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of “Stealthy” Nanomaterials. https://app.cochat.ai/papers/10.3389/fbioe.2020.00166
- The paper
- Rampado, R., Crotti, S., Caliceti, P., Pucciarelli, S., & Agostini, M. (2020). Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of “Stealthy” Nanomaterials. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2020.00166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.